Sorrento Resists M&A Frenzy
US Biotech Rejects Unsolicited Bid
Two pharma companies have made an offer for Sorrento Therapeutics that could triple the pain management and immune-oncology specialist's value but the San Diego-based group is holding firm.
You may also be interested in...
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.